| Not Yet Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma NCT07522476 | Virogin Biotech Ltd. | Phase 2 |
| Not Yet Recruiting | A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC NCT07432568 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma NCT06728410 | Mehmet Akce | Phase 2 |
| Recruiting | Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Ch NCT07201519 | Michael J Cavnar, MD | Phase 2 |
| Recruiting | REGULUS: MRI-guided Adaptive SABR for Liver Cancers NCT07223307 | Stanford University | Phase 2 |
| Recruiting | Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) NCT06990659 | University Hospital, Angers | N/A |
| Recruiting | Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy NCT06910722 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ So NCT07169734 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Can NCT06888063 | Erasmus Medical Center | Phase 2 |
| Recruiting | Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Po NCT06664021 | Anhui Provincial Hospital | Phase 2 |
| Recruiting | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patien NCT06583993 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma NCT06567600 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Withdrawn | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT06572189 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Recruiting | GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC NCT06505486 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC NCT06643208 | Fujian Provincial Hospital | — |
| Completed | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma NCT04834674 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Recruiting | The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy T NCT05422690 | Inova Health Care Services | Phase 2 |
| Not Yet Recruiting | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrah NCT06417606 | Zhiyong Huang | Phase 4 |
| Not Yet Recruiting | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Chola NCT06313554 | Fudan University | N/A |
| Not Yet Recruiting | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Lip NCT06375642 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Res NCT06406816 | Yongyi Zeng | EARLY_Phase 1 |
| Recruiting | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological NCT06375915 | Francesco De Cobelli | Phase 2 |
| Recruiting | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Ad NCT06298968 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Terminated | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HA NCT06370663 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer NCT06342414 | City of Hope Medical Center | — |
| Recruiting | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and NCT06296563 | Lei ZHAO | Phase 2 |
| Recruiting | HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable NCT06313203 | Oslo University Hospital | Phase 2 |
| Completed | A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma NCT06290739 | West China Hospital | — |
| Recruiting | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability NCT05223816 | Virogin Biotech Canada Ltd | Phase 2 |
| Recruiting | Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholan NCT06208462 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA) NCT06098547 | Azienda Sanitaria Ospedaliera | N/A |
| Recruiting | Liver Transplantation in Intrahepatic Cholangiocarcinoma NCT06140134 | Rutgers, The State University of New Jersey | — |
| Recruiting | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alteratio NCT06160752 | Tyra Biosciences, Inc | Phase 1 |
| Unknown | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards NCT05681949 | Charite University, Berlin, Germany | N/A |
| Unknown | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer NCT06134193 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277 | University of California, Davis | N/A |
| Active Not Recruiting | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid NCT05712356 | Lisata Therapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Ben NCT05896956 | RenJi Hospital | — |
| Unknown | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma NCT05913661 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III St NCT05342194 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Unknown | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma NCT05400902 | Binkui Li | Phase 2 |
| Recruiting | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC NCT06335927 | Fudan University | Phase 2 |
| Recruiting | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence NCT05557578 | Zhejiang Cancer Hospital | Phase 2 |
| Completed | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study NCT05930119 | Hutchmed | Phase 1 |
| Unknown | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Re NCT05672537 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Chola NCT05644743 | Chengjun Sui,MD | — |
| Unknown | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC NCT05781958 | Shen Feng | Phase 2 |
| Terminated | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements NCT05565794 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Active Not Recruiting | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma NCT06239532 | Qilu Hospital of Shandong University | Phase 2 |
| Unknown | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma NCT05535647 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the T NCT05285358 | City of Hope Medical Center | Phase 1 |
| Completed | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma NCT05678218 | Erasmus Medical Center | — |
| Unknown | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma NCT05290116 | Yunfei Yuan | Phase 2 |
| Completed | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer NCT05239169 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Active Not Recruiting | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements NCT05174650 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Terminated | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alteratio NCT05242822 | Kinnate Biopharma | Phase 1 |
| Terminated | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors NCT05220722 | TriSalus Life Sciences, Inc. | Phase 1 / Phase 2 |
| Unknown | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangio NCT05247996 | The Central Hospital of Lishui City | N/A |
| Completed | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Meta NCT05236699 | Tongji Hospital | Phase 2 |
| Unknown | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholang NCT05251662 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Withdrawn | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer NCT05292443 | Geneplus-Beijing Co. Ltd. | — |
| Completed | Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment NCT05328167 | Thomas Jefferson University | Phase 2 |
| Withdrawn | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC NCT05019677 | Fudan University | Phase 2 |
| Terminated | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer NCT05009953 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinom NCT05010668 | Fudan University | Phase 2 |
| Recruiting | Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Canc NCT05010681 | Fudan University | Phase 2 |
| Recruiting | TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT04954781 | Fudan University | Phase 2 |
| Unknown | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC NCT04961970 | Shi Ming | Phase 3 |
| Unknown | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangioca NCT04961788 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With C NCT04891289 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Infusion System for Hepatic Cancer NCT04684862 | Ronald DeMatteo, M.D. | N/A |
| Withdrawn | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncolog NCT04546828 | Samsung Medical Center | Phase 2 |
| Active Not Recruiting | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Rese NCT04669496 | Shanghai Zhongshan Hospital | Phase 2 / Phase 3 |
| Withdrawn | Hepatic Artery Infusion (HAI) Program at Duke University NCT04511793 | Michael Lidsky, M.D. | N/A |
| Unknown | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma NCT05327907 | Qilu Hospital of Shandong University | — |
| Completed | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other NCT04526106 | Elevar Therapeutics | Phase 1 / Phase 2 |
| Withdrawn | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma NCT04479904 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Active Not Recruiting | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery NCT04295317 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study NCT04454905 | Sun Yat-sen University | Phase 2 |
| Terminated | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer NCT04561453 | University of Washington | — |
| Recruiting | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma NCT04299581 | Fudan University | Phase 2 |
| Recruiting | Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TES NCT04556214 | Oslo University Hospital | N/A |
| Recruiting | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma NCT04078230 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Active Not Recruiting | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) NCT04238637 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma NCT03796819 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Suspended | Lenvatinib Plus PD-1 Antibody for Unresectable ICC NCT03779100 | Shi Ming | Phase 2 |
| Completed | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations NCT03781934 | Medivir | Phase 1 / Phase 2 |
| Withdrawn | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma NCT03801499 | Sun Yat-sen University | Phase 2 |
| Unknown | HAIC Versus Systemic Chemotherapy for Unresectable ICC NCT03771846 | Shi Ming | Phase 3 |
| Unknown | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma NCT03633773 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 / Phase 2 |
| Unknown | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma NCT03086993 | Delcath Systems Inc. | Phase 2 / Phase 3 |
| Terminated | Liver Transplantation for Early Intrahepatic Cholangiocarcinoma NCT02878473 | University Health Network, Toronto | Phase 2 |
| Unknown | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma NCT03521219 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Completed | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced NCT03230318 | Basilea Pharmaceutica | Phase 2 |
| Completed | HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma NCT05489692 | Sun Yat-sen University | — |
| Withdrawn | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients NCT03081039 | University of Louisville | Phase 3 |
| Completed | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT03251443 | Peking Union Medical College Hospital | Phase 2 |
| Terminated | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With NCT02807181 | Sirtex Medical | Phase 2 / Phase 3 |
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Bortezomib in Intrahepatic Cholangiocellular Carcinoma NCT03345303 | Zhengang Yuan | Phase 3 |
| Terminated | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Underg NCT02881554 | University of Washington | N/A |
| Completed | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor T NCT02762721 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | — |
| Withdrawn | Treat Primary and Metastatic Liver Tumors NCT05240040 | Methodist Health System | — |
| Unknown | TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection NCT02588755 | Eastern Hepatobiliary Surgery Hospital | N/A |
| Unknown | Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma NCT02526771 | Eastern Hepatobiliary Surgery Hospital | N/A |
| Terminated | Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma NCT02512692 | Medical University of South Carolina | N/A |
| Completed | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or An NCT02273739 | Celgene | Phase 1 / Phase 2 |
| Completed | RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma NCT03320980 | Moscow Clinical Scientific Center | — |
| Terminated | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC NCT02254681 | Allina Health System | Phase 2 |
| Unknown | Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer NCT02238613 | 307 Hospital of PLA | N/A |
| Terminated | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carc NCT02415036 | Delcath Systems Inc. | Phase 2 |
| Unknown | Next Generation Sequencing in Intrahepatic Cholangiocarcinoma NCT02184871 | University of Bologna | — |
| Completed | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treat NCT01938729 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma NCT01954745 | Massachusetts General Hospital | Phase 2 |
| Completed | Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcita NCT01862315 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma NCT01862276 | Kansai Hepatobiliary Oncology Group | — |
| Withdrawn | Response of Hepatic Tumors to Radioembolization NCT01775280 | University of Zurich | Phase 2 |
| Unknown | VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Media NCT01917370 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients NCT01914289 | Eastern Hepatobiliary Surgery Hospital | N/A |
| Completed | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma NCT01668134 | Washington University School of Medicine | Phase 1 |
| Completed | Stereotactic Body Radiotherapy for Liver Tumors NCT01347333 | Mercy Research | N/A |
| No Longer Available | Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alte NCT04087876 | Basilea Pharmaceutica | — |